Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting

Clinical and Experimental Rheumatology

Volumn 25, Issue 2, 2007, Pages 231-238

  Vázquez, Ivonne ^a   Graell, Eduard ^a   Gratacós, Jordi ^b   Cañete, Juan D ^a   Viñas, Odette ^a   Ercilla, Maria G ^a   Gómez, Antoni ^b   Hernández, Maria V ^a   Rodríguez Cros, José R ^a   Larrosa, Marta ^b   Sanmartí, Raimon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Parc Taulí Health Corporation   (Spain)

Author keywords

DMARD; Early; Prognosis; Remission; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD SALT; HEMOGLOBIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MARKER; METHOTREXATE; METHYLPREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOGENETICS; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEINURIA; RADIOGRAPHY; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GOLD SODIUM THIOMALATE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249850243     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. SHERRER YS, BLOCH DA, MITCHELL DM, YOUNG DY, FRIES JF: The development of disability in rheumatoid arthritis. Arthritis Rheum 1986; 29: 494-500.
2. LINDQVIST E, SAXNE T, GEBOREK P, EBERHARDT K: Ten-year outcome in a cohort of patients with early rheumatoid arthritis: Health status, disease process and damage. Ann Rheum Dis 2002; 61: 1055-9.
3. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004; 364; 263-69.
4. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatois arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
5. PINALS RS, MASI AT, LARSEN RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
6. PREVOO MLL, VAN GESTEL AM, VAN'T HOF M, VAN RIJSWIJK MH, VAN DE PUTTE LBA, VAN RIEL P: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association criteria in relation to the disease activity score. Br J Rheumatol 1996; 35:1101-5.
7. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. VAN RIEL PLCM,IFRANSEN J: To be in remission or not: is that the question? Ann Rheum Dis 2005; 64: 1389-90.
9. MÄKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropiate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
10. FRANSEN J, VAN RIEL PLCM: The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S93-9.
11. ALETAHA D, SMOLEN J: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S100-8.
12. GOSSEC L, DOUGADOS M, GOUPILLE P et al.: Prognostic factors for remission in early rheumatoid arthritis: A multi-parameter prospective study. Ann Rheum Dis 2004; 63: 675-80.
13. EBERHARDT K, FEX E: Clinical course and remission rate in patients with early rheumatoid arthritis: Relationship to outcome after 5 years. Br J Rheumatol 1998; 37: 1324-9.
14. VERSTAPPEN SMM, VAN ALBADA-KUIPERS GA, BIJLSMA JW, BLAAUW AAM, SCHENK Y, HAANEN HCM, AND JACOBS JWG ON BEHALF OF THE UTRECHT RHEUMATOID ARTHRITIS COHORT STUDY GROUP: A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005; 64: 38-43.
15. MÖTÖNEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
16. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
17. VAN GESTEL AM, PREVOO MLL, VAN'T HOF MA, RIJSWIK MH, VAN DE PUTTE LBA, VAN RIEL PLCM: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
18. KIRWAN JR: Using the Larsen index to assess radiographic progression in rheumatoid arthritis. J Rheumatol 2000; 27: 264-8.
19. BRUYNESTEYN K, VAN DER HEIJDE D, BOERS M et al.: Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: Preliminary results of a validation study with clinical experts. J Rheumatol 2001; 28: 904-10.
20. SESIN CA, BINGHAM CO: RemissiWn in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005; 35: 185-96.
21. PAULUS HE: Defining remission in rheumatoid arthritis: What is it? Does it matter? J Rheumatol 2004; 31: 1-4.
22. ALETAHA D, WARD MM, MACHOLD KP, NELL VPK, STAMM T, SMOLEN J: Remission and active disease in rheumatoid arthritis. Arthritis Rheum 2005; 52: 2625-36.
23. BALSA A, CARMONA L, GONZÁLEZ-ÁLVARO I, BELMONTE MA, TENA X, AND SANMARTÍ R, FOR THE EMECAR STUDY GROUP: Value of disease activity 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-6.
24. FRANSEN J, CREEMERS MCW, VAN RIEL PLCM: Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-55.
25. SVENSSON B, SCHAUFELBERGER C, TELEMAN A, AND THEANDER J FOR THE BARFOT STUDY GROUP: Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology (Oxford) 2000; 39: 1031-36.
26. TEIR J, GRAY J, PENDLEBURY A, GRENNAN DM et al.: Outcome of patients with early rheumatoid arthritis over a two year period. Ann Rheum Dis 1999; 58: 323.
27. GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patiens with early rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005; 52: 3381-90.
28. ST CLAIR EW, VAN DER HEIJDE DMFM, SMOLEN JS et al. for the Active-Controlled Study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004; 50: 3432-43.
29. RAMSAY PL, BREEDVELD FC, WEISMAN MH et al. FOR THE PREMIER INVESTIGATORS: The PREMIER Study. A multi-center, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
30. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
31. PEASE CT, BHAKTA BB, DEVLIN J, EMERY P: Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38: 228-34.
32. RAU R, HERBORN G, MENNINGER H, SANGHA O: Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002; 41: 196-204.
33. RAU R, HERBORN G, MENNINGER H, SANGHA O: Progression in early rheumatoid arthritis: 12 month results from a randomised controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998; 37: 1220-6.
34. SVENSSON B, BOONEN A, ALBERTSSON K, VAN DER HEIJDE D, KELLER C AND HAFSTRÖM I FOR THE BARFOT STUDY CONTROL: Low-dose prednisolone in addition to the initial disease-modifying anti-rheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. Arthritis Rheum 2005; 52: 3360-70.
35. MOLENAAR ETH, VOSKUYL AE, DINANT HJ, BEZEMER PD, BOERS M, DIJKMANS BAC: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 36-42.